Apexigen (APGN) via Brookline Capital Acq (BCAC) deck

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents.

Debarshi Ghosh

This post is for subscribers only

Subscribe

Already have an account? Log in